VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PRPHProPhase Labs, Inc.
$0.09$431541
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPRPHCash Flow

ProPhase Labs, Inc. (PRPH) Cash Flow Statement

30Y historyFree accessUpdated daily

Liquidity is critically constrained, as evidenced by a current ratio of 0.06 and a highly erratic OCF/NI ratio that reached -2.35 in 2025Q4, indicating an inability to sustain organic cash generation.

PRPH Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations-8.34M-17.54M-11.35M28.55M-13.62M-2.59M-841K-2.12M-2.84M-472K-3.5M-3.22M1.14M-5.73M-2.11M-3.55M445K-3.06M-1.31M956.94K4.27M4.66M-966.23K543.64K-1.12M-1.87M1.3M8.9M9M-1.1M
Operating CF Margin %-192.04%-259.05%-25.57%23.28%-17.23%-17.86%-8.52%-16.14%-28.76%-2.25%-16.97%-14.57%4.54%-25.57%-12.08%-24.47%2.25%-14.91%-3.32%2.27%7.95%10.6%-2.33%1.85%-4.53%-9.66%5.24%24.45%12.82%-137.5%
Operating CF Growth %52.42%-54.55%-139.75%309.64%-425.42%-208.2%60.31%25.33%-501.27%86.5%-8.74%-382.85%119.85%-171.77%40.6%-897.53%114.55%-133.12%-237.06%-77.57%-8.47%582.29%-277.73%148.67%40.27%-243.83%-85.39%-1.11%918.18%-
Net Income-23.39M-49.52M-16.78M18.46M6.27M-2.13M-3.15M-1.74M41.83M-2.87M-3.6M-7.83M405K-1.09M-2.71M-3.5M-3.84M-5.53M-2.46M-1.75M3.22M452.86K674.57K-6.45M215.96K-5.2M-4.2M6.8M21M-700K
Depreciation & Amortization5.06M6.64M6.7M5.06M3.56M458K398K383K337K426K367K277K243K252K355K363K522K743.67K996.16K1.33M1.4M622.35K473.59K409.07K490.24K364.92K200K200K100K0
Stock-Based Compensation1.89M3.64M3.54M3.99M3.18M1.46M744K634K78K1K135K1.04M269K246K631K192K00000000000000
Deferred Taxes07.15M0-138K557K-1.89M12K130K-17.99M0-144K-1.05M-269K02.68M3.47M0000000000400K200K-200K0
Other Non-Cash Items8.28M-334K896K5.52M-311K118K40K170K-26.67M24K135K4.62M269K-1.02M-2.84M-4.23M764K234.27K39.54K26.36K94.84K-695.83K71.03K2.84M-254.22K355.03K100K800K100K1.2M
Working Capital Changes-185K14.89M-5.7M-4.34M-26.88M-608K1.11M-1.7M-421K1.95M-390K-274K220K-4.11M-223K158K3M1.5M111.03K1.35M-450.15K4.28M-2.19M3.74M-1.57M2.61M4.6M900K-13.1M-500K
Change in Receivables736K4.74M718K-4.5M-30.47M-1.04M936K-1.02M3.83M-1.77M1.84M-517K90K-2.19M1.62M-1.19M2.48M0-135.32M00000000000
Change in Inventory313K1.36M135K702K-1.75M-1.47M444K-372K1.21M1.59M-1.04M-771K-470K637K-891K451K963K1.13M-549.52K-362.04K-445.38K1.2M773.86K1.56M794.85K-515.07K400K1.2M-7.4M0
Change in Payables-722K5.07M3.48M-1.12M2.45M3.34M-14K-125K-1.59M1.17M323K-344K-285K411K396K-219K-212K0-347.79M00000000000
Cash from Investing920K2.42M-1.37M-2.08M-19.67M-1.02M5.54M11.86M21.77M-651K-709K-306K-442K-310K-134K-1.15M272K-183.07K-533.03K-579.2K-519.21K-4.61M-555.02K-580.86K-477.96K-706.39K-1.2M-1.2M-200K-300K
Capital Expenditures0-906K-3.15M-3.92M-4.23M-1.69M-228K-140K-208K-651K-718K-312K-442K-310K-300K-1.15M-208K-199.76K-533.03K-697.48K-531.21K-310.14K-555.02K-580.86K-368.32K-393.48K-1M-1M-100K0
CapEx % of Revenue-13.38%7.11%3.2%5.35%11.64%2.31%1.07%2.11%3.1%3.48%1.41%1.77%1.38%1.72%7.95%1.05%0.97%1.35%1.66%0.99%0.71%1.34%1.97%1.49%2.03%4.03%2.75%0.14%-
Acquisitions00-2.9M452K-9.07M-2.5M228K140K40.83M09K0000000000-4.3M000-312.92K0000
Investments------------------------------
Other Investing920K-46K524K452K-700K3.89M-228K-139K40.83M-651K9K6K-442K-310K166K-1.15M480K16.7K-533.03M118.28K12K000-109.64K0-200K-200K-100K-300K
Cash from Financing6.84M14.19M5.76M-26.02M35.13M9.99M-5.82M-11.36M-16.2M-100K2.94M4.81M371K1.07M-449K133K127K63.91K173.16K493.85K-1.23M2.92M16.25K3.25M-30.13K-48.44K-14.4M-4.9M14.2M500K
Debt Issued (Net)3.31M5.61M10.52M-7.04M-45K10M00-1.5M-100K1.4M-100K-100K000000-1.46M-1.43M2.89M00000000
Equity Issued (Net)3.56M7.59M-5.97M-2.15M39.72M000-16.28M01.56M4.91M444K1.07M-449K0063.91K173.16K1.96M201.02K26.99K16.25K3.25M-30.13K-48.44K-14.4M-8.4M2.5M500K
Dividends Paid000-9.35M-4.55M0-5.82M-11.7M0000000000000000000000
Share Repurchases00-5.97M-9.63M-917K000-16.28M00000-449K000000000-30.13K-113.44K-14.8M-9.1M00
Other Financing-35K978K1.2M-7.47M0-10K0338K1.58M0-20K027K00133K127K910000000003.5M11.7M0
Net Change in Cash-588K-931K-6.96M451K1.84M6.38M-1.12M-1.62M2.73M-1.22M-1.26M1.29M1.07M-4.97M-2.69M-4.57M844K-3.18M-1.67M871.59K2.52M2.97M-1.5M3.21M-1.63M-2.62M-14.3M2.8M23M200K
Free Cash Flow-8.34M-18.44M-14.5M24.63M-17.85M-4.28M-1.07M-2.26M-3.05M-1.12M-4.21M-3.53M695K-6.04M-2.41M-4.7M237K-3.26M-1.84M259.46K3.73M4.35M-1.52M-37.23K-1.49M-2.26M300K7.9M8.9M-1.1M
FCF Margin %-192.04%-272.44%-32.68%20.08%-22.58%-29.5%-10.82%-17.21%-30.87%-5.34%-20.46%-15.99%2.78%-26.95%-13.8%-32.42%1.2%-15.88%-4.67%0.62%6.96%9.9%-3.67%-0.13%-6.02%-11.69%1.21%21.7%12.68%-137.5%
FCF Growth %54.76%-27.17%-158.88%237.99%-316.96%-300.47%52.68%25.84%-171.24%73.36%-19.47%-607.63%111.51%-150.79%48.79%-2083.97%107.28%-76.59%-810.94%-93.05%-14.15%385.94%-3986.61%97.49%34.38%-854.42%-96.2%-11.24%909.09%-
FCF per Share-0.98-9.67-8.4313.21-9.70-3.69-0.92-1.98-1.94-0.66-2.57-2.100.43-4.07-1.63-3.290.18-2.53-1.450.212.813.01-1.02-0.03-1.38-2.150.265.296.06-0.87
FCF Conversion (FCF/Net Income)0.57x0.33x0.68x1.55x-2.17x1.22x0.27x1.22x-0.07x0.16x0.97x0.41x2.81x5.25x0.78x1.01x-0.12x0.55x0.53x-0.55x1.33x10.29x-1.43x-0.08x-5.17x0.36x-0.31x1.31x0.43x1.57x
Interest Paid1.16M3.1M932K763K000054K000000000000000000000
Taxes Paid1.65M1.13M3M1.7M00103K01.35M00000034K43K0000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and insolvency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2025Q4)

Earnings Quality Obscured by Volatility

As reported in recent financial statements, the relationship between net income and operating cash flow is highly erratic, with OCF/NI ratios swinging from -2.35 to 3.15, suggesting that accruals and non-cash adjustments are masking the underlying instability of the company's core cash generation capabilities.

The extreme divergence between net income and operating cash flow indicates that reported earnings are not a reliable proxy for cash generation. Investors should monitor whether these fluctuations are driven by aggressive revenue recognition or the timing of insurance collections, as the lack of consistent conversion suggests a business model struggling to translate activity into liquidity.

Free Cash Flow Margin Instability

Based on the provided quarterly data, ProPhase Labs' free cash flow trajectory remains deeply inconsistent, with margins fluctuating between -195.8% and 22.2%, highlighting a persistent inability to sustain positive cash flow generation in the post-pandemic diagnostic environment as reported in recent filings.

The volatility in FCF margins suggests that the company is frequently forced to prioritize survival over long-term capital efficiency. The inability to maintain a positive FCF trajectory, even when accounting for minimal capital expenditures, implies that the current cost structure is fundamentally misaligned with the company's revenue-generating potential.

Working Capital Volatility Signals Risk

According to historical cash flow data, working capital changes have been highly unpredictable, with a significant $19.9 million swing in 2024Q4, which suggests that the company's cash position is heavily dependent on the timing of receivables and payables rather than organic operational efficiency.

Large, irregular swings in working capital often indicate challenges in managing the cash conversion cycle, particularly in the diagnostic services segment where insurance reimbursement delays are common. This instability warrants further investigation into whether the company is pulling forward cash or delaying obligations to manage its precarious liquidity position.

Cash Flow Statement Obscures Reality

As evidenced by the persistent stock-based compensation expenses, which have remained a recurring feature in the cash flow statement, the company's reported cash burn may be understated, as these non-cash charges effectively dilute shareholders while failing to address the underlying structural operating losses.

The reliance on stock-based compensation to manage cash outflows suggests that the company is attempting to preserve its limited cash reserves at the expense of equity dilution. Analysts should be wary of the fact that these adjustments do not improve the company's ability to fund its operations, but rather shift the burden of the cash burn onto the shareholder base.

PRPH — Frequently Asked Questions

Quick answers to the most common questions about buying PRPH stock.

How much cash does ProPhase Labs, Inc. (PRPH) generate from operations?

ProPhase Labs, Inc. (PRPH) generated $-8.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is ProPhase Labs, Inc.'s free cash flow?

ProPhase Labs, Inc. (PRPH) reported negative free cash flow of $8.3M in 2025, indicating capital requirements exceeded cash from operations.

What is ProPhase Labs, Inc.'s capital expenditure (CapEx)?

ProPhase Labs, Inc. (PRPH) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.